Bio‐creep in non‐inferiority clinical trials
- 30 August 2010
- journal article
- research article
- Published by Wiley in Statistics in Medicine
- Vol. 29 (27) , 2769-2780
Abstract
After a non‐inferiority clinical trial, a new therapy may be accepted as effective, even if its treatment effect is slightly smaller than the current standard. It is therefore possible that, after a series of trials where the new therapy is slightly worse than the preceding drugs, an ineffective or harmful therapy might be incorrectly declared efficacious; this is known as ‘bio‐creep’. Several factors may influence the rate at which bio‐creep occurs, including the distribution of the effects of the new agents being tested and how that changes over time, the choice of active comparator, the method used to account for the variability of the estimate of the effect of the active comparator, and changes in the effect of the active comparator from one trial to the next (violations of the constancy assumption). We performed a simulation study to examine which of these factors might lead to bio‐creep and found that bio‐creep was rare, except when the constancy assumption was violated. Copyright © 2010 John Wiley & Sons, Ltd.Keywords
This publication has 13 references indexed in Scilit:
- Current issues in non‐inferiority trialsStatistics in Medicine, 2007
- Alternatives for Discounting in the Analysis of Noninferiority TrialsJournal of Biopharmaceutical Statistics, 2004
- Randomized Phase III Trial of Pemetrexed Versus Docetaxel in Patients With Non–Small-Cell Lung Cancer Previously Treated With ChemotherapyJournal of Clinical Oncology, 2004
- Assessing treatment efficacy in noninferiority trialsControlled Clinical Trials, 2003
- TACT method for non‐inferiority testing in active controlled trialsStatistics in Medicine, 2002
- Non‐inferiority trials: design concepts and issues – the encounters of academic consultants in statisticsStatistics in Medicine, 2002
- Some fundamental issues with non‐inferiority testing in active controlled trialsStatistics in Medicine, 2002
- Non‐inferiority trials: the ‘at least as good as’ criterionStatistics in Medicine, 2002
- Design and analysis of non‐inferiority mortality trials in oncologyStatistics in Medicine, 2002
- Statistical Methods for Comparison to Placebo in Active-Control TrialsDrug Information Journal, 2001